US75629V1044
© Globe Newswire
08.12.2025
RXRX
LISTED
NASDAQ
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
News Preview
SALT LAKE CITY, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical-stage TechBio company decoding biology to radically improve lives, today announced positive Phase 1b/2 data from the ongoing TUPELO trial of REC-4881, an investigational allosteric MEK1/2 inhibitor for familial adenomatous polyposis (FAP)....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.12.2025
RXRX
LISTED
NASDAQ
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025
News Preview
Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a new clinical readout from the ongoing TUPELO Phase 1b/2 trial of REC-4881 in FAP at an upcoming company webinar. The webinar will be held on Decembe...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
RXRX
LISTED
NASDAQ
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
SALT LAKE CITY, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its third quarter ended September 30, 2025....
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
05.11.2025
RXRX
LISTED
NASDAQ
Recursion Announces CEO Transition Plan to Drive Next Phase of Growth
News Preview
Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and President Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and President...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
28.10.2025
RXRX
LISTED
NASDAQ
Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th
News Preview
Company to host public (L)earnings call on November 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT Company to host public (L)earnings call on November 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.07.2025
RXRX
LISTED
NASDAQ
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th
News Preview
Company to host public (L)earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST Company to host public (L)earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.06.2025
RXRX
LISTED
NASDAQ
MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy
News Preview
Salt Lake City, UT, June 06, 2025 (GLOBE NEWSWIRE) -- Researchers at the Massachusetts Institute of Technology (MIT) Computer Science and Artificial Intelligence Lab (CSAIL) and Jameel Clinic, alongside TechBio company Recursion (NASDAQ: RXRX), today announced the open-source release of Boltz-2, a first of its kind biomolecular foundation model....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.05.2025
RXRX
LISTED
NASDAQ
Recursion to Participate in Upcoming Investor Conferences
News Preview
Salt Lake City, May 30, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.05.2025
RXRX
LISTED
NASDAQ
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
News Preview
SALT LAKE CITY, May 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its first quarter ended March 31, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.05.2025
RXRX
LISTED
NASDAQ
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
News Preview
SALT LAKE CITY, May 04, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical-stage TechBio company decoding biology to radically improve lives, today announced preliminary safety and efficacy results from its ongoing Phase 1b/2 TUPELO trial of REC-4881, an investigational, allosteric MEK1/2 inhibitor in development for Familial Adenomato...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.04.2025
RXRX
LISTED
NASDAQ
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th
News Preview
Company to host public (L)earnings call on May 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT Company to host public (L)earnings call on May 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.04.2025
RXRX
LISTED
NASDAQ
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
News Preview
Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data during the 2025 Digestive Disease Week (DDW) meeting from its ongoing Phase 1b/2 clinical trial, TUPELO, which is evaluating the safety and preliminary...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
16.04.2025
RXRX
LISTED
NASDAQ
HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data
News Preview
PHILADELPHIA, April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, has licensed its real-world data to enhance clinical trial design and an...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.04.2025
RXRX
LISTED
NASDAQ
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
News Preview
Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine's REAL Space, the world’s largest...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.02.2025
RXRX
LISTED
NASDAQ
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
News Preview
SALT LAKE CITY, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its fourth quarter and fiscal year ended December 31, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.02.2025
RXRX
LISTED
NASDAQ
Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th
News Preview
Company to host public (L)earnings call on February 28th at 8:30 am ET / 6:30 am MT / 1:30 pm GMT Company to host public (L)earnings call on February 28th at 8:30 am ET / 6:30 am MT / 1:30 pm GMT...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.02.2025
RXRX
LISTED
NASDAQ
Altitude Lab Startups Raise $154M in Capital
News Preview
The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.02.2025
RXRX
LISTED
NASDAQ
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
News Preview
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) reported 12 month data from the Phase 2 study (SYCAMORE) of REC-994, the first industry sponsored Phase 2 trial completed in Cerebral Cavernous Malformations (CCM). The Company announced in September 2024 that the signal-finding study met its primary endpoint....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
RXRX
LISTED
NASDAQ
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
News Preview
Salt Lake City, UT, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has cleared a clinical trial application (CTA) for a Phase 1 clinical trial of REC-3565,...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.12.2024
RXRX
LISTED
NASDAQ
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
News Preview
Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that on December 19, 2024, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement re...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2024
RXRX
LISTED
NASDAQ
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
News Preview
SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.11.2024
RXRX
LISTED
NASDAQ
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
News Preview
SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion creating a vertically-integrated and technology-enabled drug discovery platform. Exscient...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2024
RXRX
LISTED
NASDAQ
Recursion and Exscientia Shareholders Approve the Proposed Combination
News Preview
Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2024
RXRX
LISTED
NASDAQ
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
News Preview
SALT LAKE CITY, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its third quarter ending September 30, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2024
RXRX
LISTED
NASDAQ
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
News Preview
Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2024
RXRX
LISTED
NASDAQ
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
News Preview
SALT LAKE CITY, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a Phase 1/2 clinical trial of REC-1245, a new chemical...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.08.2024
RXRX
LISTED
NASDAQ
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
News Preview
SALT LAKE CITY, Aug. 08, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Recursion (Nasdaq: RXRX), please note that in the first bullet under "Additional Corporate Updates", the company's conference call should have been mentioned as having already taken place earlier this morning, rather than coming up later...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.08.2024
RXRX
LISTED
NASDAQ
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
News Preview
Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates and report its Q2 2024 financial results on Thursday, August 8, 2024, before the opening of the financial markets. Recursion will host a L(earnings) C...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.06.2024
RXRX
LISTED
NASDAQ
Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
News Preview
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock at a price to the public of $6.5...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2024
RXRX
LISTED
NASDAQ
Recursion Announces Proposed Offering of Class A Common Stock
News Preview
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that it intends to offer and sell $200.0 million of shares of its Class A common stock in an underwritten public offering. All of...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.05.2024
RXRX
LISTED
NASDAQ
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
News Preview
Published open-access today in Nature Genetics, “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel evidence of a proximity bias in CRISPR-Cas9 gene knockouts and a debiasing (correcting) algorithm. Published open-access today in Nature Genetics, “High-resolution genome-wide mapp...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.05.2024
RXRX
LISTED
NASDAQ
Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
News Preview
Dr. Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneur Dr. Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneur...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.05.2024
RXRX
LISTED
NASDAQ
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
News Preview
BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024. BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as o...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.05.2024
RXRX
LISTED
NASDAQ
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
News Preview
Company to host public L(earnings) Call on May 9 at 5:00 pm ET Company to host public L(earnings) Call on May 9 at 5:00 pm ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.05.2024
RXRX
LISTED
NASDAQ
Recursion to Participate in Upcoming Investor Conferences
News Preview
SALT LAKE CITY, May 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences:...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
